Biliary Atresia Management

Introduction

• Biliary atresia is a severe medical condition that requires prompt attention, with an incidence of approximately 1 in 2,500 live births, and can be identified by clinical indicators such as acholic (pale) stools and dark urine 1

Surgical Intervention

• Surgical intervention with Kasai portoenterostomy before 60 days of age is critical, as success rates decrease significantly if performed after 3 months of age, according to the American Association for the Study of Liver Diseases 2
• Liver transplantation has excellent outcomes in children with biliary atresia, with a 1-year survival of 93% and 5-year survival >85%, as reported by the American Association for the Study of Liver Diseases 2
• Partial external biliary diversion is recommended if diagnosed before cirrhosis development, as stated by the American Association for the Study of Liver Diseases 2
• Liver transplantation is required if cirrhosis is established or if biliary diversion is unsuccessful, according to the American Association for the Study of Liver Diseases 2

Nutrition Support

• For infants requiring parenteral nutrition, the American Society for Parenteral and Enteral Nutrition recommends using 20% intravenous lipid emulsions rather than 10% emulsions 3
• Lipids should be administered as continuous infusions over 24 hours in newborns, as suggested by the American Society for Parenteral and Enteral Nutrition 3
• Carnitine supplementation (20-30 mg/kg/d) should be considered for premature infants on exclusive parenteral nutrition for >4 weeks, according to the American Society for Parenteral and Enteral Nutrition 3
• Patients with cholestatic liver disease should receive fat-soluble vitamin supplementation (A, D, E, K), calcium supplementation (1000-1200 mg/day), and vitamin D (400-800 IU/day) as core nutritional interventions to prevent complications and improve outcomes, as recommended by the European Association for the Study of the Liver 4

Disease Monitoring and Prevention

• Checking serum levels along with phenotype (e.g. protein deficiency) can help identify patients at risk, as reported by the American College of Medical Genetics 1
• For infants with successful Kasai procedures, monitoring for development of cirrhosis and portal hypertension is crucial, as they may eventually require liver transplantation, according to the American Association for the Study of Liver Diseases 2
• Neonatal cholestasis is defined as conjugated hyperbilirubinemia persisting beyond 2-3 weeks after birth, and represents a severe medical condition that requires prompt attention as it may indicate serious underlying hepatobiliary disorders 1
• Alpha-1-antitrypsin phenotype (MM: normal; ZZ or SZ: abnormal) should be tested as part of the diagnostic approach 1
• A complete hepatic profile, hemogram, renal function, and electrolytes should be included in the laboratory tests 4
• Abdominal ultrasound findings, such as gallbladder size and contractility, biliary tract dilatation, triangular cord sign, and liver parenchymal abnormalities, can help differentiate intrahepatic from extrahepatic causes of cholestasis 4
• The American Association for the Study of Liver Diseases recommends abdominal ultrasound as the first line to differentiate intrahepatic from extrahepatic cholestasis 4
• Next-generation sequencing panels for cholestasis-related genes, including bile acid transporters, tight junction proteins, and hepatic development genes, should be considered early in the evaluation pathway after ruling out biliary atresia and treatable disorders 1

Diagnostic Approach

Management of Complications

• Bezafibrate or cholestyramine are recommended as first-line treatments for pruritus, with rifampicin as a second-line option, with a strength of evidence level of moderate 4
• Naltrexone (oral opiate antagonist, 25-50mg daily) is recommended as a third-line treatment, starting at a low dose (12.5mg) to avoid opiate withdrawal-like reactions 4
• Sertraline (25-75mg daily) is recommended as a fourth-line treatment for cholestasis-associated pruritus 4
• Supportive measures to manage pruritus include using emollients to prevent skin dryness, avoiding hot baths or showers, using cooling gels (e.g., menthol) for affected skin areas, and keeping nails shortened to minimize skin damage from scratching 6
• Patients with advanced cholestatic liver disease should be monitored for varices (platelet count <200,000/mm³, serum albumin <40 g/L, and serum bilirubin >20 μmol/L are risk factors) and hepatocellular carcinoma 4

Follow-up and Monitoring

• Monitoring of liver function tests every 3 months in stable patients, and electrolytes, calcium, magnesium, phosphate, and albumin every 3 months is recommended 7
• Trace elements, vitamins A, E, D, B12, and folate should be monitored every 12 months 7
• Patients on treatments like bezafibrate require monitoring of liver function tests and serum creatinine, with a strength of evidence level of moderate 4